HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Quinidine

HCID 441074
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
56-54-2
Standard SMILES
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12
InChIKey
LOUPRKONTZGTKE-LHHVKLHASA-N
Molecular formula
C20H24N2O2
Average molar mass
324.4 g/mol
Monoisotopic mass
324.18377801

Overview

Crystals or white powder. (NTP, 1992)

Names & identifiers

Preferred name
Quinidine
IUPAC
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
English name
Quinidine
Molecular formula
C20H24N2O2
Molecular weight
324.42

Names & synonyms

quinidine56-54-2Conquinine(+)-QuinidinePitayine(9S)-6'-Methoxycinchonan-9-ol(8R,9S)-QuinidineConchininQuinidexChinidinbeta-QuinineConchinine
Show more names
QUNIDINEQUINDINE(S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanolCin-quinQuinaglute6-METHOXY-A-(5-VINYL-2-QUINUCLIDINYL)-4-QUINOLINE-METHANOL
Kinidinbeta-QuinidineQuiniduranCinchonan-9-ol, 6'-methoxy-, (9S)-DTXSID4023549alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanolITX08688JL(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol

Database identifiers

CAS
56-54-2
PubChem CID
441074
DTXSID
DTXSID4023549
ChEMBL
CHEMBL1294
ChEBI
CHEBI:28593
UNII
ITX08688JL
EC Number
200-279-0
Nikkaji
J4.570E

Properties

Computed structural properties

XLogP
2.9
Topological polar surface area
45.6 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
4
Rotatable bonds
4
Heavy atoms
24
Formal charge
0
Complexity
457

Experimental & physicochemical properties

Chemical ClassesBiological Agents -> Plant Toxins
DrugsPharmaceuticals -> Listed in ZINC15
SpringerMaterials PropertiesCrystal structure
LogP · 3 items

log Kow = 2.88

2.6

2.77

Color/FormCRYSTALS WITH 2.5 MOL WATER OF CRYSTALLIZATION; CRYSTALS FROM DILUTE ALCOHOL
Solubility · 5 items

less than 0.1 mg/mL at 64 °F (NTP, 1992)

Lustrous needles; decomposes at 259 °C (drug); specific optical rotation at 20 °C/D + 200 deg ; sol in 60 parts water, freely soluble in hot water, in alcohol, chloroform, slightly in ether; neutral reaction. /Quinidine hydrochloride monohydrate/

1 g /quinidine/ dissolves in about 36 ml alcohol, 56 ml ether, 1.6 ml chloroform; very soluble in methanol; practically insoluble in petroleum ether.

Soluble in benzene

In water, 140 mg/l @ 25 °C

Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Antiarrhythmics

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (98.1%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 52 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationREACH registered substance: Quinidine (EC: 200-279-0)
Other Safety InformationIMAP assessments - Cinchonan-9-ol, 6'-methoxy-, (9S)-: Environment tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this compound are not available. It is probably combustible. (NTP, 1992)
Health Hazards · 1 item

SYMPTOMS: Symptoms of exposure to this compound may include anorexia, nausea, vomiting, abdominal cramps, diarrhea, tinnitus, impaired hearing, blurred vision, vertigo, severe emotional reactions, pyrexia, skin eruptions, thrombocytopenic purpura, asthma, urticaria, acute hemolytic anemia, heart block, diminished cardiac output, ventricular tachycardia, ventricular fibrillation or acute ventricular asystole, headache, confusion, skin rash and angioedema.

Hazards Summary · 1 item

Quinidine sulfate has elicited contact allergy in production workers, and patch test with quinine were negative. [Kanerva, p. 435] Quinidine may induce photosensitivity in patients taking it systemically (photodrug reaction). [Marks, p. 201-3] As an oral medication, quinidine is used to treat heart arrhythmias. Many side effects have been reported after ingestion of therapeutic doses, including immune hemolytic anemia and drug-induced hepatitis. [HSDB] Therapeutic serum levels are 2-4 mg/L, and serious adverse effects are unusual in that range. A one gram dose is potentially lethal to adults. Toxic effects include ventricular tachycardia and depression of cardiac contractility. Other symptoms are vomiting, diarrhea, and anticholinergic effects. Seizures and coma may follow. Symptoms of chronic poisoning (cinchonism) are tinnitus, vertigo, deafness, and visual disturbances. [Olson, p. 398-9]

Chemistry & industry

Pharmacology

ATC Code · 2 items

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingFrom 6.5 to 16.2 µmol/L, 80 to 88% of quinidine is bound to plasma proteins, mainly α1-acid glycoprotein and albumin. This fraction is lower in pregnant women, and it may be as low as 50 to 70% in infants and neonates.
Pharmacodynamics · 1 item

Quinidine is an antimalarial schizonticide, and a class Ia antiarrhythmic agent used to interrupt or prevent reentrant arrhythmias and arrhythmias due to increased automaticity, such as atrial flutter, atrial fibrillation, and paroxysmal supraventricular tachycardia. In most patients, quinidine can lead to an increase in the sinus rate. Quinidine also causes a marked prolongation of the QT interval in a dose-related manner, acts peripherally as an α-adrenergic antagonist, and has anticholinergic and negative inotropic activity. The QT interval prolongation caused by quinidine can lead to increased ventricular automaticity and polymorphic ventricular tachycardias, such as _torsades de pointes_. The risk of _torsades_ is increased by bradycardia, hypokalemia, hypomagnesemia or high serum levels of quinidine. However, this type of rhythm disturbance may appear in the absence of any of them. Patients treated with quinidine may also be at risk of a paradoxical increase in ventricular rate in atrial flutter/fibrillation, and patients with sick sinus syndrome treated with quinidine may develop marked sinus node depression and bradycardia.

Mechanism of Action · 6 items

Quinidine has a complex electrophysiological profile that has not been fully elucidated. The antiarrhythmic actions of this drug are mediated through effects on sodium channels in Purkinje fibers. Quinidine blocks the rapid sodium channel (I<sub>Na</sub>), decreasing the phase zero of rapid depolarization of the action potential. Quinidine also reduces repolarizing K<sup>+</sup> currents (I<sub>Kr</sub>, I<sub>Ks</sub>), the inward rectifier potassium current (I<sub>K1</sub>), and the transient outward potassium current I<sub>to</sub>, as well as the L-type calcium current I<sub>Ca</sub> and the late I<sub>Na</sub> inward current. The reduction of these currents leads to the prolongation of the action potential duration. By shortening the plateau but prolonging late depolarization, quinidine facilitates the formation of early afterdepolarisation (EAD). Additionally, in patients with malaria, quinidine acts primarily as an intra-erythrocytic schizonticide, and is gametocidal to _Plasmodium vivax_ and _P. malariae_, but not to _P. falciparum_.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Pharmaceuticals

DecompositionWhen heated to decomposition it emits toxic fumes of oxides of nitrogen.
Melting Point · 5 items

331 to 336 °F (NTP, 1992)

174-175 °C after drying of solvated crystals

Prisms from dilute alcohol; loses one-half water in air; MP: about 168 °C /Hemipentahydrate/

Crystals from water; mp: 248 °C (dry); readily soluble in hot water, alcohol. /Quinidine methiodide monohydrate/

174 °C

Optical Rotation · 2 items

Specific optical rotation @ 15 °C/D + 230 deg (concn by volume = 1.8 in chloroform); specific optical rotation @ 17 °C/D + 258 deg (alcohol); +322 deg (concn by volume = 1.6 in 2 M HCl); UV absorption spectrum is identical with that of quinine; blue fluorescence in dilute H2SO4.

MAX ABSORPTION (METHANOL): 230 NM (LOG E= 4.53); 280 NM (LOG E= 3.54); 336 NM (LOG E= 3.69); SPECIFIC OPTICAL ROTATION (ALCOHOL) @ 25 °C/D +212 DEG

Physical Description · 3 items

Crystals or white powder. (NTP, 1992)

Triboluminescent solid; [Merck Index]

Solid

Stability/Shelf Life · 1 item

Quinidine gluconate, quinidine polygalacturonate, and quinidine sulfate darken on exposure to light and should be stored in well-closed, light resistant containers. Solutions of quinidine salts slowly acquire a brownish tint on exposure to light. Only colorless, clear solutions of quinidine gluconate injection should be used. Quinidine gluconate injection should be stored at 15-30 °C. When diluted to a concentration of 16 mg/ml with 5% dextrose injection, quinidine gluconate injection is stable for 24 hours at room temperature and up to 48 hours when refrigerated. /Quinidine salts/

Physicochemical properties

Melting point
168 · 168-172 °C(lit.)
alpha
256 · 256 º (c=1, EtOH)
Boiling point
462.75 °C · 462.75°C (rough estimate)
Density
1.1294 · 1.1294 (rough estimate)
refractive index
1.57 · 1.5700 (estimate)
storage temp.
2 · Keep in dark place,Sealed in dry,2-8°C
solubility
2 O; · insoluble in H2O; ≥10.32 mg/mL in EtOH with ultrasonic; ≥11.95 mg/mL in DMSO
form
Powder
pka
5.4 · 5.4, 10.0(at 20℃)
color
White to off-white
optical activity
20 · [α]20/D +265±5°, c = 0.8% in ethanol (dry matter)
Water Solubility
0.05 g/100 · 0.05 g/100 mL (20 ºC)
Sensitive
Light Sensitive
Merck
14 · 14,8060
BRN
91866 · 91866
BCS Class
1 · 1
Stability
Stable. Incompatible with strong oxidizing agents.
InChI
1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
InChIKey
LOUPRKONTZGTKE-LHHVKLHASA-N
SMILES
COc1ccc2nccc([C@H](O)C3CC4CCN3C[C@@H]4C=C)c2c1
LogP
3.44 · 3.440
CAS DataBase Reference
56 · 56-54-2(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
8688 JL · ITX08688JL
NCI Drug Dictionary
quinidine
ATC code
1 BA01 · C01BA01
NIST Chemistry Reference
Quinine(56-54-2)
EPA Substance Registry System
Quinidine (56-54-2)
UNSPSC Code
12352103 · 12352103
NACRES
22 · NA.22
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301-H317
Precautionary statements
261 · P261-P264-P270-P280-P301+P310-P302+P352
PPE
95 · dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Codes
Xn
Risk Statements
22 · 22-20/21/22
Safety Statements
36 · 36-22
RIDADR
2811 · UN 2811 6.1/PG 3
WGK Germany
3 · 3
RTECS
4725000 · VA4725000
F
8 · 8
TSCA
TSCA listed
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
29392000 · 29392000
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 OralSkin · Acute Tox. 3 OralSkin Sens. 1
Hazardous Substances Data
56 · 56-54-2(Hazardous Substances Data)
Toxicity
50 in · LD50 in rats (mg/kg): 30 i.v., 263 orally (Dietmann)
REACH Registrations
Active
Limited Quantities
5 kg · 5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
FDA Requirements · 2 items

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl quinidine gluconate and quinidine sulfate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Quinidine gluconate and quinidine sulfate/

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Reactive GroupAlcohols and Polyols
Special Reports · 5 items

Anderson JL; Clinical Implications of New Studies in the Treatment of Benign, Potentially Malignant and Malignant Ventricular Arrhythmias. Am J Cardiol 65 (4): 36B-42B (1990). For purposes of clinical management, ventricular arrhythmias have been divided into risk categories of benign, prognostically important (potentially malignant) and malignant. For malignant arrhythmias, class IA agents (procainamide and quinidine) continue to be the standard of treatment.

Kim SY, Benowitz NL; Poisoning Due to Class IA Antiarrhythmic Drugs: Quinidine, Procainamide and Disopyramide. Drug Saf 5 (Nov-Dec): 393-420 (1990). A review of poisoning due to quinidine is presented, including the mechanism of toxicity, clinical features, pharmacokinetics, drug interactions, and clinical management with sodium bicarbonate and potassium and accelerated drug removal with dialysis.

Kirchbaum DW; Combination Drug Therapy for Ventricular Arrhythmias. Clin Pharm 7(Nov): 808-19 (1988). The use of combined therapy with antiarrhythmic agents in patients with ventricular arrhythmias in whom single drug therapy has been ineffective or poorly tolerated is reviewed. Pairs of drugs showing the most promise have been a class IA drug (procainamide, quinidine or disopyramide) with a class IB drug (usually mexiletine) or a class IA drug with a beta-blocker.

Knobler H et al; Quinidine Induced Hepatitis: Common and Reversible Hypersensitivity Reaction. Arch Intern Med 146 (Mar): 526-8 (1986). A review of 33 cases of hepatitis attributed to quinidine occurring over a 10 yr period at one hospital was presented. Clinical and histological features of the syndrome were described. A hypersensitivity mechanism was suggested for the reaction.

Huang SK, Marcus FI; Antiarrhythmic Drug Therapy of Ventricular Arrhythmias. Curr Probl Cardiol 11 (4): 177-240 (1986). Congestive heart failure is associated with hypoperfusion to various organs including the sites of drug clearance, ie the liver and kidneys. It also leads to organ congestion as seen in the liver and gut. Not all adverse reactions to drugs that may occur in heart failure are the result of alterations in pharmacokinetics; rather, some may be due to important drug interactions. An interaction may occur directly eg reduction of renal clearance of digoxin by captopril and quinidine; or indirectly, e.g., through diuretic induced hypokalemia, which exacerbate arrhythmias associated with digoxin and antiarrhythmics such as quinidine and procainamide.

Air and Water ReactionsInsoluble in water.
CERCLA Reportable Quantities · 1 item

Persons in charge of vessels or facilities are required to notify the National Response Center (NRC) immediately, when there is a release of this designated hazardous substance, in an amount equal to or greater than its reportable quantity of 5,000 lb or 2270 kg. The toll- free- telephone number of the NRC is (800) 424-8802; in the Washington metropolitan area (202) 426-2675. The rule for determining when notification is required is stated in 40 CFR 302.6 (see section IV. D.3.b).

Hazard Classes and CategoriesAcute Tox. 3 (98.1%)

Safety & protection

Fire FightingFires involving this compound can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Storage Conditions · 2 items

Quinidine should be stored at controlled room temperature. Quinidine salts slowly discolor on exposure to light, aquiring a brownish tint. Only clear, colorless solutions are suitable for injection./intravenous quinidine gluconate/

You should store this material in the refrigerator.

Cleanup Methods · 1 item

If a spill of this chemical occurs, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with acetone and transfer the dampened material to a suitable container. Use absorbent paper dampened with acetone to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for disposal Solvent wash all contaminated surfaces with acetone followed by washing with a soap and water solution. Do not reenter the comtaminated area until safty officer has verified that the area has been properly cleaned.

Nonfire Spill Response · 1 item

SMALL SPILLS AND LEAKAGE: If a spill of this chemical occurs, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with acetone and transfer the dampened material to a suitable container. Use absorbent paper dampened with acetone to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with acetone followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Disposal Methods · 1 item

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

Isolation and EvacuationExcerpt from ERG Guide 154 [Substances - Toxic and/or Corrosive (Non-Combustible)]:
Personal Protective Equipment (PPE) · 1 item

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxicology

Interactions · 5 items

The combination of propranolol and quinidine resulted in increased beta-blockade measured by reduction in exercise heart rate and prolongation of the QTc and PR intervals ... quinidine stereoselectively inhibits the metabolism of propranolol through inhibition of the debrisoquin isozyme. The increased concentration of propranolol produced by quinidine results in increased beta-blockade.

Ethacrynic acid and furosemide /diuretics/ increase lipid solubility and tubular reabsorption of quinidine and thus prolong its therapeutic effects/ ...but will not alkalinize urine... .

Quinidine may potentiate the effects of both nondepolarizing and depolarizing skeletal muscle relaxants such as pancuronium bromide, succinylcholine chloride, and tubocurarine chloride. Neostigmine methylsulfate does not appear to reverse these effects.

Quinidine should be used with caution, if at all, in patients with myasthenia gravis and the dose of anticholinesterase drugs such as neostigmine and pyridostigmine may have to be increased. Since quinidine antagonizes the effect of vagal excitation on the atria and AV node, the administration of cholinergic drugs or any other procedures to enhance vagal activity may fail to terminate paroxysmal supraventricular tachycardia in patients receiving quinidine. The anticholinergic effects of quinidine may be additive with those of anticholinergic drugs.

For more Interactions (Complete) data for QUINIDINE (24 total), please visit the HSDB record page.

Hepatotoxicity · 1 item

Chronic therapy with quinidine is associated with a low rate of serum enzyme elevations, which are usually mild, asymptomatic and self limited even without alteration in dose. In addition, there have been many reports of acute hypersensitivity reactions to quinidine that include hepatic involvement. The reactions usually arise after 1 to 2 weeks of therapy, but can appear within 24 hours of restarting quinidine or with rechallenge. The clinical features are marked by fatigue, nausea, vomiting, diffuse muscle aches, arthralgias and high fever. Blood testing at an early stage shows increases in serum aminotransferase and alkaline phosphatase levels as well as mild jaundice, which can deepen for a few days even after stopping quinidine. The pattern of serum enzymes elevations is typically cholestatic or mixed. Rash is uncommon and eosinophilia is not typical, despite the presence of other signs of hypersensitivity (fever, arthralgias). Autoantibodies are not typically found. Liver biopsies usually show mild injury and small epithelioid granulomas, as are often found in many organs during systemic hypersensitivity reactions. A similar clinical signature of liver injury occurs with quinine, an optical isomer of quinidine that is used predominantly as an antimalarial agent. In recent years, there have been few reports of liver injury attributed to quinidine, probably because it is now rarely used.

Adverse Effects · 2 items

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.

Although quinidine is effective in managing specific conditions, the drug is associated with various adverse effects affecting bodily systems, as listed below.

Milk ConcentrationsSince quinidine is distributed into milk, the drug should be used with extreme caution in nursing women.
Toxicity Summary · 2 items

IDENTIFICATION: Quinidine is a class lA antiarrhythmic drug. Origin of the substance: Quinidine is the d- isomer of quinine. Quinidine is an alkaloid that may be derived from various species of Cinchona. Cinchona barks contain 0.25 to 3.0% quinidine. Quinidine is also prepared from quinine. Quinidine is a powder or white crystals, odorless with a bitter taste. Quinidine bisulfate is colorless crystals which is odorless and has a bitter taste. Quinidine gluconate is a white powder which is odorless and has a bitter taste. Quinidine poly-galacturonate is a powder. Quinidine sulfate is a white powder or odorless crystals with a bitter taste. Indications: Description: Premature ventricular extrasystoles and ventricular tachycardia; supraventricular arrhythmia; maintenance of sinus rhythm after cardioversion of atrial flutter or fibrillation. HUMAN EXPOSURE: Main risks and target organs: Cardio-toxicity is the main risk of quinidine poisoning. Quinidine may induce central nervous system symptoms. Summary of clinical effects: Toxic effects appear within 2 - 4 hours after ingestion but the delay may vary according to the quinidine salt and to the preparation forms. Symptoms may include disturbances of cardiac rhythm (especially in patients with underlying cardiovascular disease), neurotoxicity and respiratory depression. Diagnosis: Cardiac disturbances: circulatory arrest, shock, conduction disturbances, ventricular arrhythmias, ECG changes, Neurological symptoms: tinnitus, drowsiness, syncope, coma, convulsions, delirium. Respiratory depression. Quinidine concentrations may be helpful in diagnosis but are not useful for clinical management. Contraindications: Allergy or idiosyncrasy to cinchona alkaloids; atrioventricular or complete heart block; intraventricular conduction defects; absence of atrial activity; digitalis intoxication; myasthenia gravis and ventricular dysrhythmia of the torsades de pointes type Precautions include the following: Congestive heart failure, hypotension, renal disease, hepatic failure; concurrent use of other antiarrhythmic drugs; old age and breast-feeding. Routes of entry: Oral: Oral absorption is the most frequent cause of intoxication. Parenteral: Intoxication after IV administration is rare but has been reported in patients treated with IV quinidine for cardiac dysrhythmia. Absorption by route of exposure: Oral: Quinidine is almost completely absorbed from the gastrointestinal tract. However, because of hepatic first-pass effect, the absolute bioavailability is about 70 to 80% of the ingested dose and may vary between patients and preparations. The time to plasma peak concentration is 1 to 3 hours for quinidine sulfate, 3 to 6 hours for quinidine gluconate and about 6 hours for quinidine polygalacturonate. Sustained-release quinidine is absorbed continuously over 8 to 12 hours. Parenteral: Absorption of quinidine after intramuscular injection may be erratic and unpredictable with incomplete absorption of the administered dose, probably due to precipitation of drug at the site of injection. Other studies indicate no difference between the rate of quinidine absorption when given by intramuscular injection or oral absorption. Distribution by route of exposure: Oral: Protein binding: About 70 to 80% of the drug is bound to plasma protein. Plasma protein binding is decreased in patients with chronic liver disease. Tissue: Quinidine concentrations in liver are 10 to 30 times higher than those in plasma. Skeletal and cardiac muscle, brain and other tissues contain intermediate amounts. The red cell plasma partition ratio is 0.82. Biological half-life by route of exposure: Elimination half-life: The half-life is about 6 to 7 hours. It is increased in chronic liver disease and in the elderly. It does not appear to be altered in congestive heart failure or renal failure. Metabolism: 50 to 90% of quinidine is metabolized in the liver to hydroxylated products. Metabolites include 3-hydroxyquinidine, 2 oxoquinidinone, 0-desmethylquinidine, quinidine-N-oxide. The principal metabolite is 3 hydroxyquinidine which exerts similar effects to quinidine and may account for part of the observed antiarrhythmic effects. The elimination kinetics of hydroxyquinidine appear to be similar to those of quinidine. Elimination by route of exposure Kidney: The amount excreted unchanged in urine is variable but is about 17% of an administered dose. Up to 50% of a dose of quinidine (unchanged + metabolites) is excreted in urine within 24 hours after administration. Renal excretion is dependent upon the pH of the urine. Excretion varies inversely with urine pH. Excretion is reduced in renal insufficiency and in congestive heart failure. Liver: 50 to 90% of a dose of quinidine is metabolized in the liver. Bile: Approximately 1 to 3% is excreted in the feces via the bile. Breast milk: Quinidine is excreted in breast milk. Mode of action Toxicodynamics: Quinidine reduces the permeability of heart muscle to electrolytes (membrane stabilizer) and is a general cardiac depressant. It has a negative inotropic effect; inhibits the spontaneous diastolic depolarization; slow conduction; lengthens the effective refractory period; and raises the electrical threshold. This results in depression of contractility, impaired conductivity (atrioventricular and intraventricular) and decreased excitability but with possible abnormal stimulus re-entry mechanism. Quinidine has an anticholinergic effect and peripheral vasodilator properties. In experimental studies the following progression changes was observed: ECG: bradycardia, prolongation of the PR interval, lengthening of the QT interval, widening of the QRS with development of an idioventricular rhythm and then in ventricular standstill. Sometimes the terminal event was ventricular fibrillation. Blood pressure decreases progressively. A significant decrease of blood pressure was noted with the appearance of QRS widening and blood pressure was close to zero when slow idioventricular rhythm appeared. Electrolytes abnormalities: decrease in plasma concentrations of potassium, sodium and magnesium with the development of acidosis. Electrolytes: Hypokalaemia may occur and is probably related to an intracellular transport of potassium by a direct effect on cellular membrane permeability. Neurologic symptoms: Syncope and convulsions may represent a direct toxic effect on CNS or may be related to cerebral ischaemia due to circulatory or respiratory failure. Pharmacodynamics: Quinidine slows the rate of firing of the normal and of ectopic rhythmic foci; it raises the threshold for electrically induced arrhythmias; it protects against ventricular arrhythmias; and it prevents or terminates circus movement flutter. Teratogenicity: Quinidine has been implicated as a cause of light cranial nerve damage to the fetus at doses much larger than those needed to treat arrhythmias. Interactions: Several interactions have been reported. Quinidine has a synergistic action with warfarin (decrease of prothrombin level). Quinidine potentiates both non-depolarizing and depolarizing neuromuscular blocking agents. The cardiodepressant effects of other antiarrhythmic agents are increased by concurrent use of quinidine; amiodarone increases quinidine concentrations in the blood. Quinidine concentrations are reduced by: rifampicin, anticonvulsants, nifedipine and acetazolamide. Quinidine concentrations are increased by antacids, cimetidine, verapamil and amiodarone; the risk of quinidine toxicity is increased by terfenadine, astemizole, and thiazide and loop diuretics. Quinidine increases the plasma concentrations of propafenone and digoxin. Main adverse effects: Numerous adverse effects during quinidine therapy have been reported. Cardiovascular: Hypotension after IV administration; Syncope; proarrhythmic effect: "torsades de pointes"; and ECG: widening of QRS interval; prolongation of PR and QT intervals. CNS: Cinchonism: headache, fever, visual disturbances, mydriasis, tinnitus, nausea, vomiting and rashes. Gastrointestinal: Nausea, vomiting, diarrhoea, colic have been reported. Hepatic: Granulomatous hepatitis or hepatitis with centrilobular necrosis. Skin: Skin rashes with drug fever and photosensitivity may result. Hematologic: Thrombocytopenia (immunologic reaction) has been noted. Clinical effects: Acute poisoning: Ingestion: Severity of quinidine poisoning is related to the cardiotoxic effects. Symptoms appear usually within 2 to 4 hours and may include: cardiovascular symptoms: hypotension, cardiogenic shock, cardiac arrest. ECG may show: decrease of T wave; prolongation of QT and QRS intervals; atrioventricular block; ventricular dysrhythmia (torsade de pointes). Neurological symptoms: tinnitus, drowsiness, syncope, coma, convulsion, blurred vision and diplopia. Respiratory symptoms: hypoventilation and apnea. Cardiotoxicity may be enhanced if other cardiotoxic drugs have been ingested (antiarrhythmic drugs, tricyclic antidepressants). Parenteral exposure: After IV administration symptoms appear more rapidly. Chronic poisoning: Ingestion: The most relevant symptoms of chronic poisoning are: ECG disturbances; syncope due to ventricular dysrhythmia, (torsade de pointes) and cinchonism gastrointestinal disturbances Course, prognosis, cause of death: The usual course of quinidine poisoning is dominated by the cardiovascular disturbances which usually occur within 2 to 4 first hours but may first appear as late as 12 hours after exposure (and perhaps even later after ingestion of a slow- release preparation). Symptoms may last for 24 to 36 hours. Patients who survive 48 hours after acute poisoning are likely to recover. Death may result from cardiac arrest by asystole or electromechanical dissociation and, rarely, by ventricular fibrillation. Systematic description of clinical effects: Cardiovascular: Acute: Cardiovascular symptoms are the major features of quinidine toxicity. Tachycardia due to anticholinergic effects is usually observed initially or in moderate intoxication. In severe intoxication, bradycardia due to atrioventricular block may occur. Hypotension and shock: hypotension due to peripheral vasodilation is common. In severe intoxication, cardiogenic shock with increased central venous pressure is usually observed and is related to decreased cardiac contractility. Cardiac arrest may occur, which may be related to electromechanical dissociation, ventricular dysrhythmia or asystole. Cardiac dysrhythmias are common and may include: atrioventricular block, idioventricular rhythm, ventricular tachycardia and fibrillation, torsades de pointes. ECG changes are always present in symptomatic intoxication: repolarization abnormalities, decreased T wave, increase of U wave, prolongation of QT and PR intervals, widening of QRS complexes (> 0.08 sec), atrioventricular block. Syncope due to torsade de pointes may occur. Chronic: ECG changes with repolarization abnormalities, decreased T wave and increase of QT interval are a common feature during quinidine therapy. Syncope is related to transient torsade de pointes and occurs in 1 to 8% of patients receiving quinidine. The occurrence of torsade de pointes is not correlated with plasma quinidine levels but is favored by an increase in the QT interval. Respiratory: Acute: Respiratory depression or apnea is mostly associated with severe cardiac disturbances such as shock or ventricular dysrhythmia. Pulmonary edema with normal pulmonary capillary wedge pressure following an attempted suicide has been documented. Neurological: CNS: Acute: Drowsiness, delirium, coma and convulsions may appear without cardiac symptoms. However, cardiac failure should always be considered when CNS symptoms appear. Cinchonism may sometimes appear. Chronic: Cinchonism. Delirium has been reported. Peripheral nervous system: Chronic: Quinidine can potentiate the neuromuscular blocking action of some skeletal muscle relaxants and may cause the return of respiratory paralysis if it is given shortly after recovery from neuromuscular blockade. Autonomic nervous system: Acute: Quinidine has an anticholinergic effect. However, this effect is usually limited to the vagal system. Skeletal and smooth muscle: Chronic: An increase in serum concentrations of skeletal muscle enzymes has been reported in a man treated with quinidine. Gastrointestinal: Acute: Nausea and vomiting may occur. Chronic: Gastrointestinal toxicity (nausea, vomiting, diarrhea and colic) is the most frequent side effect of quinidine. Hepatic: Chronic: Hepatotoxicity has been reported, with an increase in serum concentrations of transaminases, LDH, alkaline phosphatase, and cholestasis. Renal: Acute: No direct nephrotoxic effect has been reported. Acute renal failure related to cardiogenic shock may occur. Dermatological: Chronic: Skin lesions have been attributed to the use of quinidine and include skin rash, photosensitivity and lichen planus. Eye, ear, nose, throat: local effects: Acute: Cinchonism is rarely observed in acute poisonings. Toxic amblyopia, scotoma and impaired color perception may occur at toxic doses. Chronic: Chronic cumulative overdose may cause cinchonism: headache, tinnitus, vertigo, mydriasis, blurred vision, diplopia, photophobia, deafness, and corneal deposits have been reported in a patient who took quinidine for two years. Hematological: Chronic: Thrombocytopenia and hemolytic anemia of immunologic origins have been reported. Immunological: Chronic: Quinidine may cause several immunologic mediated reactions: thrombocytopenia, hemolytic anemia, angioneurotic edema, skin rash, fever. Metabolic: Acid-base disturbances: Acute: Metabolic acidosis may occur in severe intoxication with shock. Fluid and electrolyte disturbances: Acute: Hypokalemia is frequently observed. Special risks: Pregnancy: Chronic: Quinidine has been implicated as a cause of cranial nerve damage to the fetus at doses much larger than those needed to treat arrhythmia. In a neonate born to a woman taking quinidine throughout pregnancy, serum levels were equal to that of the mother. The child's ECG was normal and there was no evidence of teratogenicity. Breast-feeding: Chronic: Quinidine is present in breast milk at levels slightly lower than serum levels. The dose of quinidine received by an infant taking 1l of milk would be below therapeutic doses. However, breast-feeding is not recommended because of potential quinidine accumulation in the immature newborn liver.

Natural Pollution Sources · 2 items

Obtained from various species of Cinchona and their hybrids and from Remijia pedunculata Fluckiger (Fam Rubiaceae).

Quinidine is a stereoisomer of quinine and occurs in cinchona bark in amounts ranging from 0.3 to over 1%, although in some barks it may be practically absent.

Human Toxicity Excerpts · 5 items

/SIGNS AND SYMPTOMS/ The /cardiac/ conduction velocity decreases progressively as drug concentrations rise, as reflected by increases in the PR interval, QRS duration and QT interval. High plasma quinidine levels cause high-grade atrioventricular block, bundle-branch block, and asystole resembling that of hyperkalemia.

/SIGNS AND SYMPTOMS/ Quinidine is a antiarrhythmic drug in the class 1A category. This drug has a low toxic to therapeutic ratio, and its use is associated with a number of serious adverse effects during long term therapy and life threatening sequelae following acute overdose. ... Severe intoxication with the class 1A agents may result from acute accidental or intentional overdose, or from accumulation of the drugs during long term therapy. Acute overdose can result in severe disturbances of cardiac conduction and hypotension, frequently accompanied by central nervous system toxicity.

/CASE REPORTS/ A patient is described with quinidine induced acute lymphadenopathy syndrome proven by rechallenge of the drug. Serum markers for systemic lupus were negative.

/CASE REPORTS/ Pulmonary edema developed after a suicidal 8 gram quinidine ingestion with normal pulmonary capillary wedge pressures.

/CASE REPORTS/ Fever is a well-known side effect of quinidine therapy, but an elevated white blood cell count is considered unusual. Two patients are described who had leukocytosis or a marked left shift in the white blood cell count (or both) in association with quinidine fever. Neither patient had evidence of infection. In each of these patients, the temperature and white blood cell count returned to normal within two days after quinidine was discontinued. Although infection should always be considered in a patient with fever, leukocytosis, and a left shift, these may also appear in association with quinidine therapy.

Artificial Pollution SourcesFound in quinidine sulfate mother liquors. /Quinidine sulfate/
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

quinidine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Antidote and Emergency Treatment · 1 item

Decontamination. 1. Prehospital. Administer activated charcoal if available. Do not induce vomiting because of the risk of abrupt onset of seizures and coma. 2. Hospital. Administer activated charcoal. Consider gastric lavage for large ingestions. /Quinidine and other type Ia antiarrhythmic drugs/

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Non-Human Toxicity Values · 5 items

LD50 Rat iv 30.0 mg/kg

LD50 Rat i.v. 23 mg/kg

LD50 Rat oral 263 mg/kg

LD50 Mouse i.p. 170 mg/kg

For more Non-Human Toxicity Values (Complete) data for QUINIDINE (7 total), please visit the HSDB record page.

Regulatory information

FDA Requirements · 2 items

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl quinidine gluconate and quinidine sulfate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Quinidine gluconate and quinidine sulfate/

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

CERCLA Reportable Quantities · 1 item

Persons in charge of vessels or facilities are required to notify the National Response Center (NRC) immediately, when there is a release of this designated hazardous substance, in an amount equal to or greater than its reportable quantity of 5,000 lb or 2270 kg. The toll- free- telephone number of the NRC is (800) 424-8802; in the Washington metropolitan area (202) 426-2675. The rule for determining when notification is required is stated in 40 CFR 302.6 (see section IV. D.3.b).

Safety data

F
8
PPE
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
wgk
3
tsca
TSCA listed
rtecs
VA4725000
ridadr
UN 2811 6.1/PG 3
hs_code
29392000
Toxicity
LD50 in rats (mg/kg): 30 i.v., 263 orally (Dietmann)
risk_code
22-20/21/22
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
Xn
safety_code
36-22
hazard_class
6.1(b)
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301-H317
Limited Quantities
5.0 kg (11 lbs) (solid)
Excepted Quantities
Max Inner Pack (30g or 30ml) and Max Outer Pack (1Kg or 1L)
REACH Registrations
Active
Hazard Classifications
Acute Tox. 3 OralSkin Sens. 1
Precautionary statements
P261-P264-P270-P280-P301+P310-P302+P352
Hazardous Substances Data
56-54-2(Hazardous Substances Data)

The exact mechanism of antiarrhythmic action of quinidine has not been determined conclusively, but the drug is considered a class I (membrane stabilizing) antiarrhythmic agent. Like other class I antiarrhythmic agents, quinidine is believed to combine with fast sodium channels in their inactive state and thereby inhibit recovery after repolarization in a time- and voltage-dependent manner, which is associated with subsequent dissociation of the drug from the sodium channels. Quinidine exhibits electrophysiologic effects characteristic of class IA antiarrhythmic agents. The electrophysiologic characteristics of the subgroups of class I antiarrhythmic agents may be related to quantitative differences in their rates of attachment to and dissociation from transmembrane sodium channels, with class IA agents exhibiting intermediate rates of attachment and dissociation.

Like lidocaine and procainamide, quinidine suppresses automaticity in the His-Purkinje system. In usual doses, quinidine may decrease the automaticity of ectopic pacemakers, but the extent of this effect also depends upon the anticholinergic effect of the drug on the sinoatrial node, atria, and atrioventricular node. Extremely high concentrations of quinidine may increase myocardial automaticity. The drug decreases conduction velocity in the atria, ventricles, and His-Purkinje system, and may decrease or cause no change in conduction velocity through the AV node. Quinidine probably suppresses atrial fibrillation or flutter by prolonging the effective refractory period and increasing the action potential duration in atrial and ventricular muscle and in the His-Purkinje system. Because prolongation of the effective refractory period is greater than the increase in the duration of the action potential, the cardiac tissue remains refractory even after restoration of the resting membrane potential. Quinidine shortens the effective refractory period of the atrioventricular node, and the anticholinergic action of the drug may also increase the conductivity of the atrioventricular node. The effects of quinidine on refractoriness and the action potential duration of atrial fibers may be modified by the anticholinergic effects of the drug. Quinidine decreases cardiac excitability, both in diastole and in the relative refractory period, by increasing the threshold potential for electrical excitation. At therapeutic plasma concentrations, quinidine causes prolongation of the QRS complex and QT interval.

Quinidine also exhibits some antipyretic and oxytocic properties. Quinidine has a very weak curare-like action on the myoneural junction and also causes depression of skeletal muscle action potential.

Intravenous quinidine depresses contractility and decreases systemic vascular resistance primarily by alpha-adrenergic receptor blockade. High blood levels of quinidine increase left ventricular end-diastolic pressure through its negative inotropic effect. Cardiovascular collapse has resulted from depression of contractility.

Quindine primarily kills the schizont parasite at the asexual intra-erythrocytic cycle stage of the Plasmodium falciparum malaria protozoan parasite. Quinidine also kills the gametocyte parasite stages of Plasmodium malariae, Plasmodium vivax, and Plasmodium ovale.

Biological Half-Life · 3 items

The elimination half-life of quinidine is 6-8 hours in adults and 3-4 hours in pediatric patients.

Quinidine generally has a plasma half-life of 6-8 hr in healthy inividuals, but half-life may range from 3-16 hr or longer. In one study in patients with Plasmodium falciparum malaria, the elimination half-life of the drug averaged 12.8 hr (range: 6.6-24.8 hr).

The usual plasma half-life of approximately 7 hours after intravenous administration is increased in the presence of chronic liver disease.

Metabolism/Metabolites · 6 items

Quinidine is mainly metabolized in the liver by cytochrome P450 enzymes, specifically CYP3A4. The major metabolite of quinidine is 3-hydroxy-quinidine, which has a volume of distribution larger than quinidine and an elimination half-life of about 12 hours. Non-clinical and clinical studies suggest that 3-hydroxy-quinidine has approximately half the antiarrhythmic activity of quinidine; therefore, this metabolite is partly responsible for the effects detected with the chronic use of quinidine.

Lactate conjugates of quinidine and its 3-hydroxy metabolite were detected in overdose suicide patient.

Quinidine is metabolized in the liver, principally via hydroxylation to 3-hydroxyquinidine and 2-quinidinone. Some metabolites have antiarrhythmic activity. Approximately 10-50% of a dose is excreted in urine (probably by glomerular filtration) as unchanged drug within 24 hr.

Quinidine metabolites include 3-hydroxyquinidine N-oxide, 2'-oxoquinidinone, desmethylquinidine, and quinidine N-oxide. While metabolism is highly variable between individuals, at least in cases of quinidine-induced torsade de pointes, the metabolites do not appear to contribute to the formation of dysrhythmias.

Quinidine undergoes extensive hepatic oxidative metabolism... One metabolite, 3-hydroxyquinidine, is nearly as potent as quinidine in blocking cardiac sodium channels or prolonging action potentials.

Most quindiidne is eliminated hepatically via the action of cytochrome P450 IIIA.

FDA Pharmacological Classification · 6 items

ITX08688JL

QUINIDINE

Established Pharmacologic Class [EPC] - Antiarrhythmic

Established Pharmacologic Class [EPC] - Cytochrome P450 2D6 Inhibitor

Mechanisms of Action [MoA] - Cytochrome P450 2D6 Inhibitors

Quinidine is an Antiarrhythmic and Cytochrome P450 2D6 Inhibitor. The mechanism of action of quinidine is as a Cytochrome P450 2D6 Inhibitor.

MeSH Pharmacological Classification · 6 items

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Absorption, Distribution and Excretion · 6 items

The absolute bioavailability of quinidine sulfate is approximately 70%, but it ranges from 45% to 100%. The less-than-complete quinidine sulfate bioavailability is a result of first-pass metabolism in the liver. In contrast, the absolute bioavailability of quinidine gluconate ranges from 70% to 80%, and relative to quinidine sulfate, quinidine from quinidine gluconate has a bioavailability of 1.03. The tmax of quinidine sulfate extended-release tablets is approximately 6 h, while the tmax of quinidine gluconate goes from 3 to 5 h. The peak serum concentration reached with immediate-release quinidine sulfate is delayed for about an hour when taken with food. Furthermore, the ingestion of grapefruit juice may decrease the rate of absorption of quinidine.

The elimination of quinidine is achieved by the renal excretion of the unchanged drug (15 to 40% of total clearance) and its hepatic biotransformation to a variety of metabolites (60 to 85% of total clearance). When urine has a pH lower than 7, 20% of administered quinidine appears in urine unchanged. However, this proportion decreases to as little as 5% as it becomes more alkaline. The renal clearance of quinidine involves both glomerular filtration and active tubular secretion, moderated by pH-dependent tubular reabsorption.

Quinidine has a volume of distribution of 2-3 L/kg in healthy young adults, 0.5 L/kg in patients with congestive heart failure, and 3-5 L/kg in patients with liver cirrhosis.

The clearance of quinidine ranges from 3 to 5 mL/min/kg in adults. In pediatric patients, quinidine clearance may be two or three times as rapid.

The volume of distribution of quinidine is 2 to 3 L/kg in healthy young adults, but this may be reduced to as little as 0.5 L/kg in patients with congestive heart failure, or increased to 3 or 5 L/kg in patients with cirrhosis of the liver. At concentrations of 2 to 5 mg/L (6.5 to 16.2 umol/L), the fraction of quinidine bound to plasma proteins (mainly to (alpha)1-acid glycoprotein and to albumin) is 80 to 88% in adults and older children, but it is lower in pregnant women, and in infants and neonates it may be as low as 50 to 70%. Because (alpha)1-glycoprotein levels are increased in response to stress, serum levels of total quinidine may be greatly increased in settings such as acute myocardial infarction, even though the serum content of unbound (active) drug may remain normal. Protein binding is also increased in chronic renal failure, but binding abruptly descends toward or below normal when heparin is administered for hemodialysis.

...Essentially completely absorbed after oral admin; max effects occur within 1-3 hr, and persist for 6-8 more hr. Large fluctuations in plasma concentration... if repeated doses are given at this interval. ...IM admin... gluconate yields peak effects in 30-90 min.

Cellular LocationsExtracellular
Metabolite PathwaysQuinidine Action Pathway

Uses & manufacturing

Uses · 3 items

Used as a human and veterinary antiarrhythmic and human antimalarial; [Merck Index]

MEDICATION

Use (kg; approx.) in Germany (2009): >500

Impurities · 2 items

Quinidine of commerce is usually accompanied by up to 20% of hydroquinidine.

Commercially available quinidine salts contain not more than 20% of the respective dihydroquinidine salt, 1% of the respective quinine salt, and 1% of the respective dihydroquinine salt as impurities.

U.S. Imports(1984) 3.37X10+9 g /QUINIDINE AND ITS SALTS/
U.S. Production(1972) PROBABLY GREATER THAN 4.54X10+5 GRAMS
Consumption Patterns100% AS A CARDIAC DEPRESSANT TO INHIBIT AURICULAR FIBRILLATION (1975)
Methods of Manufacturing · 2 items

ISOMERIZATION OF QUININE SULFATE

Quinidine may be made by treating quinine with a metallic alkoxide or by oxidizing quinine to quinone and then reducing the latter with sodium isopropoxide. It may also be obtained directly from the mother liquors remaining after removal of quinine from extracts of Cinchona; separation from cinchonine and other alkaloids is effected by special processes

Formulations/Preparations · 5 items

/Available as/ Capsules: 200and 300 mg; Injection: 200 mg/ml; Tablets: 100, 200 and 300 mg; Sustained-Release Tablets: 300 mg /Quinidine sulfate/, as Injection: 800 mg/10 ml; Extended-Release Tablets: 324 and 330 mg /Quinidine Gluconate/ and as Tablets: 275 mg /Quinidine Polygalacturonate/

Quinaglute Dura-Tabs contain 5 gr quinidine gluconate /per tablet/

Quinidex Exten-tabs contain 300 mg quinidine sulfate /per tablet/

Duraquin contains 330 mg quindine gluconate /per tablet/

For more Formulations/Preparations (Complete) data for QUINIDINE (11 total), please visit the HSDB record page.

Use ClassificationPharmaceuticals
General Manufacturing Information · 3 items

Cinchonan-9-ol, 6'-methoxy-, (9S)-: INACTIVE

Most of the material sold today is made by isomerization of quinine.

A long acting quinidine preparation /Quinidine gluconate/

Applications · 7 items

DescriptionQuinidine is a stereoisomer of the antimalarial agent quinine and a class Ia antiarrhythmic agent. Quinidine blocks the voltage-gated sodium (Nav) channel Nav1.5 in a use-dependent manner. It decreases the amplitude and duration of action potentials in isolated canine ventricular myocytes. It inhibits KKr, peak INa, and late INa (IC50s = 4.5, 11, and 12 μM, respectively) and can induce torsade de pointes in isolated rabbit hearts when used at a concentration of 1 μM. Quinidine induces QT prolongation in dogs. It also binds to M2 muscarinic acetylcholine receptors (Ki = 7.5 μM for human recombinant receptors expressed in HM2-B10 cells). Formulations containing quinidine have been used in the treatment of atrial fibrillation and ventricular arrhythmias.

DescriptionQuinidine is a commonly used class I antiarrhythmic drug. It is a stereoisomer of quinine, originally derived from the bark of the cinchona tree. It exerts its antiarrhythmic effects on the heart by interacting with the electrophysiology mechanisms that cause arrhythmias to modify the abnormalities in impulse initiation and conduction. Quinidine depresses normal automaticity in cardiac fibers that may act as ectopic pacemakers causing arrhythmias. Quinidine also blocks the slowly inactivating, tetrodotoxin-sensitive Na current, the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito.

HistoryIn 1820, the French chemists Pierre Pelletier and Joseph Caventou extracted some alkaloids from the cinchona bark, including quinine and quinidine. Subsequently, quinine was demonstrated to play a very important role in the treatment of malaria after a number of scientific researches. Quinidine is the dextroisomer of quinine and has the similar pharmacological properties as quinine, but quinidine’s effects are five to ten times stronger on the heart than quinine.

UsesQuinidine occurs in cinchona bark to about0.25–0.3% and also in cuprea bark. It is present in quinine sulfate mother liquor. Itis formed by isomerization of quinine. Itis used in the prevention of certain cardiacarrhythmias.

UsesA dextrorotatory stereoisomer of Quinine. Antiarrhythmic (class IA). Antimalarial

Usesantiarrhythmic, antimalarial

General DescriptionCrystals or white powder.

Upstream & downstream products

Downstream products

QUININE SULFATEN-Benzylquinidinium chloride

Additional notes

DefinitionChEBI: A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.

Quinidine is widely known for its potential toxicity, leading to QT prolongation, and it can trigger TdP, a life-threatening arrhythmia. As the condition can be fatal, it requires immediate management, including discontinuing the drug, closely monitoring cardiac and electrolyte levels (potassium and magnesium), and addressing any underlying hypoxia. Clinicians can effectively manage TdP by promptly administering magnesium sulfate and terminating prolonged episodes through electrical cardioversion. In refractory cases, isoproterenol or transvenous pacing may be the treatment options. In addition, hypotension can be addressed with IV fluids, and norepinephrine might be required in refractory cases.